Posted by Michael Wonder on 16 Nov 2020
CHMP adopted positive opinion for Elzonris (tagraxofusp) for the treatment of blastic plasmacytoid dendritic cell neoplasm
13 November 2020 - The CHMP recommended approval of Elzonris for the first line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm.
The Menarini Group announced today that the CHMP of the EMA has adopted a positive opinion on the approval of Elzonris (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm, an aggressive haematologic malignancy with dismal outcomes.
